SCHEMBL384643

SCHEMBL384643

Clc1cccs1.O=S(=O)(Cl)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.39
PRSS1 P07477 2/20 0.39
PRSS2 P07478 2/20 0.39
PRSS3 P35030 2/20 0.39
PKM P14618 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 2/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
TSHR P16473 1/20 0.36
DAO P14920 1/20 0.34
GSK3B P49841 1/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 2/20 0.33
CCR2 P41597 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7073829 0.87
SCHEMBL29054 0.87
Formaldehyde SCHEMBL27539590 0.84
Ammonia Solution, Strong SCHEMBL28811677 0.84
SCHEMBL3276946 0.84
SCHEMBL2975655 0.84
SCHEMBL6830319 0.84
SCHEMBL497681 0.84
Hydrogen Sulfide SCHEMBL29248841 0.84
Fluoride SCHEMBL28278490 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112125914-B 5-substituted berbamine derivatives, preparation method and application thereof 杭州卫本药业有限公司 2024-02-13 CN disclosed
CN-115385862-B Pyrimidine thioether compound containing sulfonate structure and preparation method and application thereof 贵州大学 2023-03-28 CN disclosed
CN-115385862-A Pyrimidine thioether compound containing sulfonate structure as well as preparation method and application thereof 贵州大学 2022-11-25 CN disclosed
CN-112125914-A 5-substituted berbamine derivatives, preparation method and application thereof 杭州卫本药业有限公司 2020-12-25 CN disclosed
CN-105919987-B N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives and uses thereof 约翰斯霍普金斯大学 2020-04-03 CN disclosed
EP-2509941-B1 N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES UNIV JOHNS HOPKINS (US) 2019-01-23 EP disclosed
US-20180050985-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES THE JOHNS HOPKINS UNIVERSITY 2018-02-22 US disclosed
US-9458127-B2 Bis-acylated hydroxylamine derivatives CARDIOXYL PHARMACEUTICALS, INC. (US) 2016-10-04 US disclosed
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES THE JOHNS HOPKINS UNIVERSITY 2016-02-18 US disclosed
CN-105130855-A Bis-Acylated Hydroxylamine Derivatives UNIV JOHNS HOPKINS 2015-12-09 CN disclosed
WO-2010107997-A1 THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-23 WO disclosed
US-7365196-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK SHARP & DOHME LTD. (GB) 2008-04-29 US disclosed
US-7205434-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives having a substitute on the bridgehead position; nonpeptidic compounds to treat or prevent Alzheimer's Disease by modulating the processing of amyloid precursor proteins by the putative gamma-secretas to arrest the production of beta-amyloid MERCK SHARP & DOHME LTD. (GB) 2007-04-17 US disclosed
EP-1268412-B8 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME (GB) 2007-02-21 EP disclosed
EP-1268412-B1 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME (GB) 2006-11-22 EP disclosed
US-20040186147-A1 Sulphonamides for control of beta-amyloid production MERCK SHARP & DOHME LTD. (GB) 2004-09-23 US disclosed
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives MERCK CANADA INC. (CA) 2004-02-12 US disclosed
WO-2003013506-A1 SULPHONAMIDES FOR CONTROL OF BETA-AMYLOID PRODUCTION MERCK SHARP & DOHME LIMITED (GB) 2003-02-20 WO disclosed
EP-1268412-A1 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 2003-01-02 EP disclosed
WO-2001070677-A1 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050985-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, NOS2 F2 3365/4885PRSS1 1381/4885PRSS2 1427/4885
US-20040186147-A1 Sulphonamides for control of beta-amyloid production APP, APBA1, PSEN2 F2 4669/4885PRSS1 374/4885PRSS2 1119/4885
US-20160046570-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, TNNC1 F2 3216/4885PRSS1 1269/4885PRSS2 1319/4885
US-20040029862-A1 Sulphonamido-substituted bridged bicycloalkyl derivatives BACE1, BACE2, PSEN2 F2 3951/4885PRSS1 204/4885PRSS2 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.